The GLP-1 telehealth market grew from a handful of providers in 2023 to hundreds by mid-2025. Now, the correction is underway. Providers that couldn't sustain their unit economics, that depended on a single 503B pharmacy, or that burned through venture funding without building a real clinical infrastructure — many of them are closing, merging, or quietly shutting down their GLP-1 programs.
If you're a patient, this raises a question that almost nobody in the industry wants to talk about: what happens to your treatment if your provider disappears?
The Scenario Is Already Happening
This isn't hypothetical. Patients have reported logging into their provider's portal to request a refill only to find the website offline, their account inaccessible, and no way to reach the clinical team. Others have received abrupt emails: "We are discontinuing our GLP-1 program effective [date]. Your current prescription will not be renewed."
For a patient mid-treatment on a medication that requires supervised titration and shouldn't be stopped abruptly, this is more than inconvenient — it's a medical disruption.
What You Lose When a Provider Closes
Your prescription
GLP-1 prescriptions are provider-specific. When your telehealth company shuts down, the prescribing clinician associated with your account is no longer writing your prescription. Your pharmacy won't fill a refill without an active prescriber.
Your medical records
Your intake forms, consultation notes, lab results, dose history, and side effect reports live on the provider's platform. If that platform goes offline, accessing those records becomes difficult or impossible. Under HIPAA, the provider is required to maintain your records — but enforcement on a defunct company is a challenge.
Your dose continuity
If you've titrated to a specific dose over several months and suddenly lose access to your medication, you face two bad options: stop abruptly (which can cause rebound effects and is medically inadvisable) or try to find a new provider who will continue your current dose without starting the entire intake process over.
Why This Keeps Happening
The GLP-1 telehealth market has several structural vulnerabilities that make provider shutdowns more likely than in other telehealth categories:
- 503B regulatory risk. Providers that depend entirely on 503B outsourcing facilities for their medication supply face an existential threat from FDA enforcement actions. If the FDA restricts compounded semaglutide production at 503B facilities — a scenario that's actively in play as of July 2026 — every provider without a 503A backup plan loses its supply chain overnight.
- Thin margins. At $99–$149/month for compounded semaglutide, the margins for providers who include clinical support, shipping, and marketing are razor-thin. A small increase in pharmacy costs or a drop in patient volume can flip the economics from viable to unsustainable.
- Venture-funded unsustainability. Several high-profile GLP-1 startups were funded by venture capital with the expectation of rapid growth. When growth stalls or unit economics don't improve, the funding dries up — and the provider either pivots or closes.
- Legal pressure. Novo Nordisk has filed more than 100 trademark-related lawsuits against companies using terms like "Ozempic" or "Wegovy" in their marketing. Legal costs alone have forced smaller operators to shut down.
How to Protect Yourself
You can't prevent your provider from closing. But you can minimize the disruption if it happens:
- Keep copies of your medical records. Download or request copies of your intake forms, lab results, consultation notes, and dose history. Don't rely on the provider's portal being available when you need it.
- Know your current dose and medication details. Keep a personal log of your dose, the concentration of your vial, your pharmacy's name and license number, and your prescribing clinician's name and NPI number.
- Ask about pharmacy backup plans. If your provider uses a 503B outsourcing facility, ask whether they have a 503A pharmacy relationship as a backup. Providers with diversified pharmacy sourcing are less likely to face a sudden supply cutoff.
- Avoid long prepayment commitments. Six-month bundles save money — but if the provider closes in month 3, your refund prospects are poor. Monthly billing limits your financial exposure.
- Identify a backup provider before you need one. Know which other programs accept patients at their current dose without re-titration. Some providers explicitly advertise continuity for patients transferring from other programs.
These providers have demonstrated operational stability and flexible transfer policies:
Providers Worth Investigating
We evaluated these programs based on the criteria discussed in this article. Listings are paid partnerships — our analysis is independent.